Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Ospedale di Livorno · Institute of Oncology Prof. Dr. Ion Chiricuta · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,189
total citations
- FWCI
- 133.84
- Percentile
- 100%
- References
- 26
Citations per year
Authors
13Topics & keywords
Topics
Keywords
- Erlotinib
- Medicine
- Internal medicine
- Tolerability
- Lung cancer
- Oncology
- Performance status
- Erlotinib Hydrochloride
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.